Streamex Corp. · NASDAQ:STEX
Streamex — BioSig Technologies — Investor Presentation (April 2023)
16 slides from Streamex's investor presentation, Apr 28, 2023
Slide 1: Corporate Presentation
Corporate Presentation Nasdaq: BSGM
Slide 2: Forward-looking statements
This presentation contains forward-looking statements including statements that address activities, events, or developments that BioSig expects, believes, or anticipates will or may occur in the future, such as predictions of financial performance, approvals, and launches by BioSig of new products,
Slide 3: Reimagining what's possible in cardiac care
Reimagining what’s possible in cardiac care We are a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. By leveraging a first-of-its-kind combination of hardware and software, our technology delivers unprecedented cardiac signal clarity, end
Slide 4: Growing into an expanding global market
Growing into an expanding global market $1.6B Total global addressable market 14.4 million Americans suffer from cardiac arrhythmias Atrial Fibrillation is the most common arrhythmia affecting: ~6.1 million people in the U.S. and growing ~33.5 million people worldwide Catheter ablation is fast becom
Slide 5: Presenting the PURE EP Platform
Presenting the PURE EP™ Platform Poised to disrupt the field of electrophysiology, PURE EP TM delivers unprecedented intracardiac signal purity that pushes the boundaries of cardiac arrhythmia identification. PURE EPTM offers one-of-a-kind algorithms, configurable features, and novel applications no
Slide 6: Supporting our clinical profile with data and economic value
Supporting our clinical profile with data and economic value Signal Clarity & Relevance1 In a multi-center, randomized prospective study, PURE EP™signals were compared to conventional recording and mapping systems signals: 75% of PURE EP™ signals rated superior in quality 83% of the time, physicians
Slide 7: Integrating into EP labs for improved efficiency
Integrating into EP labs for improved efficiency PURE EP™ delivers unprecedented clarity of the raw electrical signals of the heart, unburdening physicians from having to parse through interference of outputs from conventional technology–an on-going problem in EP labs.
Slide 8: Accelerating commercialization of the PURE EP Platform
Accelerating commercialization of the PURE EPTM Platform Limited market release 1.0 •Selective installations •7 centers •Learning, fixing, improving •First sale 2019-2020 Limited market release 2.0 •Expansion –17 centers •Clinical trial •Peer-reviewed publication 2021-2022 National commercial expans
Slide 9: Current footprint
Current footprint
Slide 10: Complex AF Case Study Utilizing a New Standard in Signal Processing
“Having high-quality, better signals makes a difference in almost every case. Since we installed the system in our lab, the efficiency in which we operate has significantly improved. ” ~Dhanunjaya DJ Lakkireddy, MD Kansas City Heart Rhythm Institute, Overland Park, KS Complex AF Case Study Utilizing
Slide 11: Led by strong industry experience
Led by strong industry experience Kenneth L. Londoner, MBA Founder, Chairman, Chief Executive Officer, Director Endicott Management Partners; J & W Seligman & Co.; Visiting Professor, Columbia University Gray Fleming Chief Commercial Officer St. Jude Medical; Abbott Laboratories John Sieckaus Chief
Slide 12: Maintaining well-protected IP
Maintaining well-protected IP 59 Utility and Design Patents Granted/ Allowed in the Field of Digital Signal Processing 29 Worldwide Fundamental Patents Granted/Allowed 11 Pending Applications in the U.S. 12 Pending Applications in APAC 30 Worldwide Design Patents Granted/Allowed 8 Pending Applicatio
Slide 13: Why BioSig now?
Why BioSig now? The solution Solving the critical unmet need for better intracardiac information that may improve success rates of ablation procedures. First customers are industry leaders World-renowned Medical Centers of Excellence. Disruptive and novel technology Our technology saves procedural t
Slide 14: Upcoming Events
Upcoming Events New Customer announcements* U.S. product acquisitions and expansion of footprint. Participation at Heart Rhythm 2023 in New Orleans May 19-21The largest gathering of heart rhythm professionals from around the world. Release of Clinical Data May 2023* Multiple abstracts have been acce
Slide 15: Key References
Key References Optimizing signals in the EP lab Amin Al-Ahmad, MD (Cardiac electrophysiologist - St. David's Medical Center - Texas Cardiac Arrhythmia Institute, Austin, TX – USA) – Great Debates and Updates in EP - March 2022. Click here to open Complex AF case study utilizing a new standard in sig
Slide 16: Contact us
Contact us Andy Ballou VP of Investor Relations aballou@biosigtech.com203-409-5444, x133 BioSig Technologies, Inc.55 Greens Farms RoadWestport, CT 06880 www.biosig.com
BioSig Technologies — Investor Presentation (April 2023) on 6ix